Alaunos Therapeutics Inc (TCRT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $6.86M
Last updated: Nov 17, 2026 at 4:15 PM ET
Alaunos Therapeutics Inc (TCRT) Stock Chart
Alaunos Therapeutics (TCRT) has a latest price of $1.66 on Nov 17, 2026, 63.1% below its 52-week high of $4.50. Its price fell 44.1% over the past 12 months. The month-end price fell 99.8% over the 10 years through Oct 2026, a compound annual decline of 45.6%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $1,055.47 in Apr 2017 and its lowest $0.89 in Sep 2026, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart TCRT with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for TCRT.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 11.7%, and over 6 months it fell 33.6%. The month-end price fell 83.7% over the 3 years through Oct 2026, a compound annual decline of 45.4%.
| Period | Change |
|---|---|
| 1 month | -47.0% |
| 3 months | -11.7% |
| 6 months | -33.6% |
| 12 months | -44.1% |
| 12 months, with dividends | -44.1% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -83.7% | -45.4% |
| 5 years | -99.1% | -61.3% |
| 10 years | -99.8% | -45.6% |
Price by Year
Its best calendar year was 2019, when the price rose 152.4%, and its weakest was 2023, when it fell 89.1%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $1.95 | -39.6% |
| 2025 | $3.23 | +69.6% |
| 2024 | $1.91 | -82.0% |
| 2023 | $10.60 | -89.1% |
| 2022 | $97.32 | -40.4% |
| 2021 | $163.42 | -56.7% |
| 2020 | $377.81 | -46.6% |
| 2019 | $707.65 | +152.4% |
| 2018 | $280.36 | -54.8% |
| 2017 | $620.69 | -22.6% |
Trading Range
The price is 1.0% above its 50-day average of $1.64 and 26.6% below its 200-day average of $2.26.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $1.66 | |
| 52-week high | $4.50 | -63.1% |
| 52-week low | $0.72 | +130.6% |
| 50-day average | $1.64 | +1.0% |
| 200-day average | $2.26 | -26.6% |
Price Risk
Over 3 years, its largest fall from a peak was 97.3%.
| Measure | Value |
|---|---|
| 1-year beta | 0.94 |
| Largest fall, 1 year | -83.0% |
| Largest fall, 3 years | -97.3% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About TCRT
What is TCRT's 1-year price change?
Alaunos Therapeutics's price fell 44.1% over the past 12 months. With dividends included, the 12-month total return was -44.1%.
What is TCRT's 5-year price change?
Alaunos Therapeutics's month-end price fell 99.1% over the 5 years through Oct 2026, a compound annual decline of 61.3%. These figures leave out dividends.
What is TCRT's 52-week high and low?
Alaunos Therapeutics's 52-week high is $4.50 and its 52-week low is $0.72. Its latest price of $1.66 on Nov 17, 2026 is 63.1% below the high.
What is TCRT's beta?
Alaunos Therapeutics's 1-year beta against the S&P 500 is 0.94, so its price has moved about in line with the market over the past year. Its largest fall from a peak over the past year was 83.0%.
Is the TCRT chart free?
Yes. Advanced Charting for TCRT is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
TCRT pages: Overview, Charting, Earnings, Financials, Statistics, Competitors